TDOC Teladoc Health, Inc.

NYSE Services-Offices & Clinics of Doctors of Medicine DE CIK: 0001477449
AI RATING
SELL
82% Confidence

Investment Thesis

Teladoc operates at a significant loss with declining revenue and extremely low gross margins (13.7%), indicating fundamental operational challenges in its business model. While the company maintains a fortress balance sheet with $750.7M cash and minimal debt, these reserves are being gradually consumed, providing limited runway for operational turnaround without rapid margin expansion.

Strengths

  • + Strong balance sheet with $750.7M cash and minimal leverage (0.03x debt/equity)
  • + Healthy liquidity ratios (2.80x current, 2.72x quick) providing operational flexibility
  • + Improved EPS by 80.6% YoY suggesting cost reduction initiatives underway

Risks

  • ! Persistent operating losses (-$61.8M) with contracting revenue (-1.5% YoY)
  • ! Critically low gross margin (13.7%) indicates structural unit economics problems or severe pricing pressure
  • ! Barely positive free cash flow ($7.9M or 1.3% FCF margin) is unsustainable given revenue base
  • ! Negative returns on equity (-4.8%) and assets (-2.3%) destroying shareholder value

Key Metrics to Watch

Financial Metrics

Revenue
613.8M
Net Income
-63.8M
EPS (Diluted)
$-0.36
Free Cash Flow
7.9M
Total Assets
2.8B
Cash
750.7M

Profitability Ratios

Gross Margin 13.7%
Operating Margin -10.1%
Net Margin -10.4%
ROE -4.8%
ROA -2.3%
FCF Margin 1.3%

Balance Sheet & Liquidity

Current Ratio
2.80x
Quick Ratio
2.72x
Debt/Equity
0.03x
Debt/Assets
52.4%
Interest Coverage
-10.71x
Long-term Debt
42.4M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-06T16:26:27.883084 | Data as of: 2026-03-31 | Powered by Claude AI